Pierre Conan

Mr. Pierre Conan

University of Western Brittany, Brest, Bretagne, France
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
PCPierre Conan
Pierre Conan
ALAlice Léon
Alice Léon
MGMathilde Gourdel
Mathilde Gourdel
CRClaire Rollet
Claire Rollet
LCLoubna Chaïr
Loubna Chaïr
GFGaelle Friocourt
Gaelle Friocourt
CBS encodes a pyridoxal 5′-phosphate-dependent enzyme that catalyses the condensation of homocysteine and serine to form cystathionine. Due to its implication in some cancers and in the cognitive pathophysiology of Down syndrome, the identification of pharmacological inhibitors of this enzyme is urgently required. However, thus far, attempts to identify such molecules have only led to the identification of compounds with low potency and limited selectivity. We consequently developed an original, yeast-based screening method that identified three FDA-approved drugs of the 8-hydroxyquinoline family: clioquinol, chloroxine and nitroxoline. These molecules reduce CBS enzymatic activity in different cellular models, proving that the molecular mechanisms involved in yeast phenotypic rescue are conserved in mammalian cells. A combination of genetic and chemical biology approaches also revealed the importance of copper and zinc intracellular levels in the regulation of CBS enzymatic activity—copper promoting CBS activity and zinc inhibiting its activity. Taken together, these results indicate that our effective screening approach identified three new potent CBS inhibitors and provides new findings for the regulation of CBS activity, which is crucial to develop new therapies for CBS-related human disorders.

21 November 2025 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
Lucile GentileLucile Gentile
Lucile Gentile
ANAdeel Nasir
Adeel Nasir
LSLoane Simon
Loane Simon
ATAnaëlle Timoner
Anaëlle Timoner
APAnaïs Péron
Anaïs Péron
CVCécile Voisset
Cécile Voisset
Parkinson's disease (PD) is characterized by the pathologic aggregation of α-synuclein, which induces endoplasmic reticulum (ER) stress and activates the unfolded protein response (UPR), ultimately leading to the death of dopaminergic neurons. This study investigated whether drugs known to mitigate protein aggregation in prion disease models would attenuate the stress response and cell death in PD models. Flunarizine and ten of its structural analogues, previously identified through a drug repositioning approach to reduce the aggregation of PrPSc prion protein, were evaluated in a Chinese hamster ovary (CHO-K1) cell model. First, UPR was induced in CHO-K1 cells using tunicamycin, revealing that several of these drugs conferred protection and also reduced the expression of the UPR marker CHOP. Subsequently, we tested these anti-prion drugs in PD relevant cellular models. Neuronally-differentiated PC12 cells were employed, and all 11 drugs exhibited protective effect. Finally, human dopaminergic neurons (LUHMES cells) were exposed to 1-methyl-4-phenylpyridinium (MPP+), a compound commonly used to induce parkinsonian-like pathology. In this model, all 11 drugs demonstrated cytoprotective properties and attenuated UPR. Notably, several compounds - benzydamine, duloxetine, flunarizine, metixene and triflupromazine - protected LUHMES cells from MPP+ -induced ER stress at nanomolar concentrations. These findings provide the proof of concept that drugs selected for other indications, may be repurposed to ameliorate PD and related pathologies linked to ER stress.

1 January 2026 in Human Mutation
Verified
Journal Article
Open access
PDF file
RFRasha Faraj
Rasha Faraj
AFAudrey Farrugia
Audrey Farrugia
AHAnna CE Hurst
Anna CE Hurst
PCPierre Conan
Pierre Conan
JMJennifer Martin
Jennifer Martin
GFGaelle Friocourt
Gaelle Friocourt
Neurodevelopmental disorders (NDDs) encompass a wide range of conditions often linked to genetic causes, with mutations in the X‐linked ARX gene representing a recurrent contributor. ARX encodes a transcription factor critical for GABAergic neuron development and functioning, regulating the expression of key neurodevelopmental target genes. Variants in ARX result in a wide clinical spectrum, ranging from asymptomatic female carriers to severe developmental syndromes in both sexes. This study investigates the functional impact of 16 ARX variants, including known pathogenic, likely pathogenic, and novel de novo variants, some associated with atypical presentations such as sudden infant death. Using transient expression in N2a neuroblastoma cells, we employed a comprehensive functional approach—including luciferase reporter assays, Western blotting, immunofluorescence, and RT‐qPCR—to assess protein expression levels, subcellular localization, their interaction with known corepressors (TLE1 and CtBP1), and their transcriptional activity on selected ARX ‐known targets. Our results demonstrate that all tested variants disrupt normal ARX transcriptional function, with several also altering protein localization or expression. Remarkably, a subset of variants exhibited dominant‐negative effects, offering a compelling explanation for unexpectedly severe phenotypes in female patients, likely exacerbated by skewed X‐inactivation and other modifying factors. By integrating experimental data with a literature‐based review of published ARX variants, we provide refined genotype–phenotype correlations, highlighting the importance of mutation type, positional context within key ARX functional domains, and patient sex. Altogether, this study advances our understanding of the molecular mechanisms driving ARX ‐related NDDs, emphasizing the importance of functional testing for accurate variant interpretation and paving the way toward informed genetic counseling and potential therapeutic development.

8 April 2026
Verified
Thesis
Closed access
PCPierre Conan
Pierre Conan
La trisomie 21 est une maladie génétique causée par la présence d’un chromosome 21 supplémentaire. Les patients souffrent d’une dysmorphie crâniofaciale, une cardiomyopathie et un risque accru de développer la maladie d’Alzheimer. À cela s’ajoute une déficience intellectuelle, de gravité variable suivant les patients, pour laquelle il n’existe à ce jour aucun traitement pharmacologique. De nombreuses études se sont concentrées sur l’identification des gènes dont la triplication est impliquée dans la déficience intellectuelle afin de pouvoir développer un traitement pharmacologique. Ces études ont identifié deux gènes en particulier, localisés sur le chromosome 21 : DYRK1A, codant une tyrosine kinase régulant de nombreuses voies de signalisation, et CBS, codant la Cystathionine-Beta- Synthase, responsable de la métabolisation des acides aminés soufrés et de la production d’H2S, un gazotransmetteur important pour la transmission synaptique.Mon projet de thèse consiste à identifier des candidats-médicaments capables de diminuer l’activité enzymatique de CBS. J’ai ainsi identifié deux familles de molécules prometteuses qui ont en commun une grande affinité pour les ions métalliques. De plus, nous avons caractérisé le lien génétique entre l’activité de DYRK1A et CBS. Une meilleure compréhension de la relation existant entre ces deux enzymes devrait permettre d’identifier de nouvelles stratégies thérapeutiques pour traiter la déficience intellectuelle dans la trisomie 21.